<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232012000400003</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Annual frequency and distribution of tuberculosis resistance in the public health laboratory network of Pará State, Brazil]]></article-title>
<article-title xml:lang="pt"><![CDATA[Frequência e distribuição anual de resistência da tuberculose na rede de laboratórios de saúde pública do Estado do Pará, Brasil]]></article-title>
<article-title xml:lang="es"><![CDATA[Frecuencia y distribución anual de resistencia de la tuberculosis en la red de laboratorios de salud pública del Estado de Pará, Brasil]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Maria Luiza]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conceição]]></surname>
<given-names><![CDATA[Emilyn Costa]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[Ricardo José de Paula Souza e]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Ana Roberta Fusco da]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[Karla Valéria Batista]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade do Estado do Pará Programa de Pós-graduação em Biologia Parasitária da Amazônia ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto Evandro Chagas/SVS/MS Laboratório de Geoprocessamento ]]></institution>
<addr-line><![CDATA[Ananindeua Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Instituto Evandro Chagas/SVS/MS Seção de Bacteriologia e Micologia ]]></institution>
<addr-line><![CDATA[Ananindeua Pará]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<numero>4</numero>
<fpage>27</fpage>
<lpage>33</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232012000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232012000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232012000400003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[This study described the frequency and variety of multidrug-resistant tuberculosis (MDR-TB) cases in Pará State, Brazil. In order to record the epidemiology and spacial distribution of the disease, antimicrobial susceptibility testing (AST) and the proportion method were used. The AST was performed on 848 samples at the Instituto Evandro Chagas and a central public health laboratory in that State. Of all patients enrolled in the study, 358 (42.2%) were resistant to at least one antituberculosis (anti-TB) drug. The percentage of primary, acquired resistance and combined MDR-TB was 30.4%, 69.3% and 42.2% respectively. MDR-TB was detected in 223 (26.3%) samples. Primary MDR-TB was found in 14% of previously treated patients, while 48% exhibited acquired resistance and 62% exhibited combined resistance. Of all age groups, from 25 to 36 years old (mean age 38.7 ± 15) showed the highest proportion of resistant cases (26.3%). Seven cities in the State presented 59.6% of the cases documented in the study. These findings reflect the poor quality of the healthcare for patients in these cities. We further suggest that clinicians need to observe their patients more directly during treatment and test them more often for anti-TB drug sensitivity. The number of TB cases in Pará did not vary significantly during the period studied, but researchers did notice a slight increase in the proportion of drug-resistant cases related to the total number of cases reported in Pará. This change in the resistance rates reflects the need to improve the quality of health services for TB care. A concentration of TB cases was observed in some municipalities and in the neighborhoods of the Belém City.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Este estudo descreveu a frequência e variedade de casos de tuberculose multirresistente (TBMR) no Estado do Pará, Brasil. A fim de registrar a epidemiologia e a distribuição espacial da doença, foram utilizados testes de suscetibilidade antimicrobiana (TSA) e do método proporcional (MP). O TSA foi realizado em 848 amostras no Instituto Evandro Chagas e em um laboratório central de saúde pública naquele Estado. De todos os pacientes incluídos no estudo, 358 (42,2%) eram resistentes a pelo menos um medicamento antituberculose (anti-TB). A porcentagem das resistências primária, adquirida e TBMR foi de 30,4%, 69,3% e 42,2%, respectivamente. A TBMR foi detectada em 223 (26,3%) amostras. A TBMR primária foi encontrada em 14% dos pacientes tratados anteriormente, enquanto que 48% apresentaram a resistência adquirida e 62% exibiram resistência combinada. De todos os grupos etários, o de 25-36 anos (média de idade de 38,7 ± 15) apresentou a maior proporção de casos resistentes (26%). Sete cidades do Estado apresentaram 59,6% dos casos documentados no estudo. Estes resultados refletem a baixa qualidade dos cuidados de saúde com os doentes nestas cidades. Observa-se ainda, a necessidade de maiores cuidados dos médicos para com os pacientes durante o tratamento e realização, com maior frequência, dos testes de sensibilidade aos medicamentos anti-TB. O número de casos de TB no Pará não variou significativamente durante o período estudado, porém os pesquisadores notaram um ligeiro aumento na proporção de casos resistentes aos medicamentos relacionados com o número total de casos notificados no Estado. Esta mudança nas taxas de resistência reflete a necessidade de melhorar a qualidade dos serviços de saúde para a atenção à TB. A concentração de casos de tuberculose foi observada em alguns municípios e nos bairros da Cidade de Belém.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Este estudio describe la frecuencia y variedad de casos de tuberculosis multirresistente (TBMR) en el Estado de Pará, Brasil. Con la finalidad de registrar la epidemiología y distribución espacial de la enfermedad, se utilizaron pruebas de susceptibilidad antimicrobiana (PSA) y el método proporcional (MP). El PSA fue realizado en 848 muestras del Instituto Evandro Chagas y en un laboratorio central de salud pública del Estado. De todos los pacientes incluidos en este estudio, 358 (42,2%) eran resistentes a, por lo menos, un medicamento antituberculosis (anti-TB). El porcentaje de resistencia primaria, adquirida y TBMR fue de 30,4%, 69,3% y 42,2%, respectivamente. Se detectó TBMR en 223 (26,3%) muestras. Se encontró TBMR primaria en 14% de los pacientes con tratamiento previo, mientras que un 48% presentó resistencia adquirida y 62% combinada. De todos los grupos etarios, el de 25-36 años (promedio de edad 38,7 ± 15) presentó la mayor proporción de casos resistentes (26%). Siete ciudades del Estado concentraron el 59,6% del total de casos documentados en el estudio. Estos resultados reflejan la baja calidad de cuidados en salud con los enfermos en estas ciudades. También observamos, la necesidad de mayores cuidados por parte de los médicos durante el tratamiento realizado, con mayor frecuencia, de exámenes de sensibilidad a medicamentos anti-TB. El número de casos de TB en Pará no varió significativamente durante el periodo estudiado, sin embargo, los investigadores notaron un ligero aumento en la proporción de casos resistentes a medicamentos relacionados al número total de casos notificados en el Estado. Este cambio en las tasas de resistencia refleja la necesidad de mejorar la calidad de los servicios de salud para la atención de TB. La concentración de casos de tuberculosis se observó en algunos municipios y barrios de la Ciudad de Belém.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[Multidrug-resistant]]></kwd>
<kwd lng="en"><![CDATA[Rifampicin]]></kwd>
<kwd lng="en"><![CDATA[Isoniazid]]></kwd>
<kwd lng="pt"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="pt"><![CDATA[Tuberculose]]></kwd>
<kwd lng="pt"><![CDATA[Resistência a Múltiplos Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Rifampicina]]></kwd>
<kwd lng="pt"><![CDATA[Isoniazida]]></kwd>
<kwd lng="es"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[Tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[Resistencia a Múltiples Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Rifampicina]]></kwd>
<kwd lng="es"><![CDATA[Isoniazida]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="left"><span style="line-height:115%; font-family:'Arial','sans-serif'; font-size:9.0pt; "><font color="#990033">http://dx.doi.org/10.5123/S2176-62232012000400003</font></span></p>     <p align="right"><font face="Verdana" size="2"><b>ORIGINAL ARTICLE | ARTIGO ORIGINAL |    ART&#205;CULO ORIGINAL</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b><font size="4"><a name="topo"></a>Annual frequency    and distribution of tuberculosis resistance in the public health laboratory    network of Par&#225; State, Brazil</font></b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>Frequ&#234;ncia e distribui&#231;&#227;o anual    de resist&#234;ncia da tuberculose na rede de laborat&#243;rios de sa&#250;de    p&#250;blica do Estado do Par&#225;, Brasil</b></font></p>     <p>&nbsp;</p>     <p><b><font face="Verdana" size="3">Frecuencia y distribuci&#243;n anual de resistencia    de la tuberculosis en la red de laboratorios de salud p&#250;blica del Estado    de Par&#225;, Brasil</font></b></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Maria Luiza Lopes<sup>I</sup>; Emilyn Costa    Concei&#231;&#227;o<sup>I</sup>; Ricardo Jos&#233; de Paula Souza e Guimar&#227;es<sup>II</sup>;    Ana Roberta Fusco da Costa<sup>III</sup>; Karla Val&#233;ria Batista Lima<sup>III</sup></b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><sup>I</sup><i>Programa de P&#243;s-gradua&#231;&#227;o    em Biologia Parasit&#225;ria da Amaz&#244;nia, Universidade do Estado do Par&#225;,    Bel&#233;m, Par&#225;, Brasil    <br>   </i></font><font face="Verdana" size="2"><sup>II</sup><i>Laborat&#243;rio de    Geoprocessamento, Instituto Evandro Chagas/SVS/MS, Ananindeua, Par&#225;, Brasil    <br>   </i></font><font face="Verdana" size="2"><sup>III</sup><i>Se&#231;&#227;o de    Bacteriologia e Micologia, Instituto Evandro Chagas/SVS/MS, Ananindeua, Par&#225;,    Brasil</i></font></p>     <p><font face="Verdana" size="2"><a href="#endereco">Correspondence    <br>   Endere&ccedil;o para correspond&ecirc;ncia    <br>   Direcci&oacute;n para correspondencia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1">     <p><font face="Verdana" size="2"><b></b></font><font face="Verdana" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana" size="2">This study described the frequency and variety    of multidrug-resistant tuberculosis (MDR-TB) cases in Par&#225; State, Brazil.    In order to record the epidemiology and spacial distribution of the disease,    antimicrobial susceptibility testing (AST) and the proportion method were used.    The AST was performed on 848 samples at the Instituto Evandro Chagas and a central    public health laboratory in that State. Of all patients enrolled in the study,    358 (42.2%) were resistant to at least one antituberculosis (anti-TB) drug.    The percentage of primary, acquired resistance and combined MDR-TB was 30.4%,    69.3% and 42.2% respectively. MDR-TB was detected in 223 (26.3%) samples. Primary    MDR-TB was found in 14% of previously treated patients, while 48% exhibited    acquired resistance and 62% exhibited combined resistance. Of all age groups,    from 25 to 36 years old (mean age 38.7 &plusmn; 15) showed the highest proportion    of resistant cases (26.3%). Seven cities in the State presented 59.6% of the    cases documented in the study. These findings reflect the poor quality of the    healthcare for patients in these cities. We further suggest that clinicians    need to observe their patients more directly during treatment and test them    more often for anti-TB drug sensitivity. The number of TB cases in Par&#225;    did not vary significantly during the period studied, but researchers did notice    a slight increase in the proportion of drug-resistant cases related to the total    number of cases reported in Par&#225;. This change in the resistance rates reflects    the need to improve the quality of health services for TB care. A concentration    of TB cases was observed in some municipalities and in the neighborhoods of    the Bel&#233;m City.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b>Keywords: </b><i>Mycobacterium tuberculosis;    </i>Tuberculosis; Multidrug-resistant; Rifampicin; Isoniazid.</font></p> <hr size="1">     <p><font face="Verdana" size="2"><b>RESUMO</b></font></p>     <p><font face="Verdana" size="2">Este estudo descreveu a frequ&#234;ncia e variedade    de casos de tuberculose multirresistente (TBMR) no Estado do Par&#225;, Brasil.    A fim de registrar a epidemiologia e a distribui&#231;&#227;o espacial da doen&#231;a,    foram utilizados testes de suscetibilidade antimicrobiana (TSA) e do m&#233;todo    proporcional (MP). O TSA foi realizado em 848 amostras no Instituto Evandro    Chagas e em um laborat&#243;rio central de sa&#250;de p&#250;blica naquele Estado.    De todos os pacientes inclu&#237;dos no estudo, 358 (42,2%) eram resistentes    a pelo menos um medicamento antituberculose (anti-TB). A porcentagem das resist&#234;ncias    prim&#225;ria, adquirida e TBMR foi de 30,4%, 69,3% e 42,2%, respectivamente.    A TBMR foi detectada em 223 (26,3%) amostras. A TBMR prim&#225;ria foi encontrada    em 14% dos pacientes tratados anteriormente, enquanto que 48% apresentaram a    resist&#234;ncia adquirida e 62% exibiram resist&#234;ncia combinada. De todos    os grupos et&#225;rios, o de 25-36 anos (m&#233;dia de idade de 38,7 &plusmn;    15) apresentou a maior propor&#231;&#227;o de casos resistentes (26%). Sete    cidades do Estado apresentaram 59,6% dos casos documentados no estudo. Estes    resultados refletem a baixa qualidade dos cuidados de sa&#250;de com os doentes    nestas cidades. Observa-se ainda, a necessidade de maiores cuidados dos m&#233;dicos    para com os pacientes durante o tratamento e realiza&#231;&#227;o, com maior    frequ&#234;ncia, dos testes de sensibilidade aos medicamentos anti-TB. O n&#250;mero    de casos de TB no Par&#225; n&#227;o variou significativamente durante o per&#237;odo    estudado, por&#233;m os pesquisadores notaram um ligeiro aumento na propor&#231;&#227;o    de casos resistentes aos medicamentos relacionados com o n&#250;mero total de    casos notificados no Estado. Esta mudan&#231;a nas taxas de resist&#234;ncia    reflete a necessidade de melhorar a qualidade dos servi&#231;os de sa&#250;de    para a aten&#231;&#227;o &#224; TB. A concentra&#231;&#227;o de casos de tuberculose    foi observada em alguns munic&#237;pios e nos bairros da Cidade de Bel&#233;m.</font></p>     <p><font face="Verdana" size="2"><b>Palavras-chave: </b><i>Mycobacterium tuberculosis;    </i>Tuberculose; Resist&#234;ncia a M&#250;ltiplos Medicamentos; Rifampicina;    Isoniazida.</font></p> <hr size="1">     <p><font face="Verdana" size="2"><b>RESUMEN</b></font></p>     <p><font face="Verdana" size="2">Este estudio describe la frecuencia y variedad    de casos de tuberculosis multirresistente (TBMR) en el Estado de Par&#225;,    Brasil. Con la finalidad de registrar la epidemiolog&#237;a y distribuci&#243;n    espacial de la enfermedad, se utilizaron pruebas de susceptibilidad antimicrobiana    (PSA) y el m&#233;todo proporcional (MP). El PSA fue realizado en 848 muestras    del Instituto Evandro Chagas y en un laboratorio central de salud p&#250;blica    del Estado. De todos los pacientes incluidos en este estudio, 358 (42,2%) eran    resistentes a, por lo menos, un medicamento antituberculosis (anti-TB). El porcentaje    de resistencia primaria, adquirida y TBMR fue de 30,4%, 69,3% y 42,2%, respectivamente.    Se detect&#243; TBMR en 223 (26,3%) muestras. Se encontr&#243; TBMR primaria    en 14% de los pacientes con tratamiento previo, mientras que un 48% present&#243;    resistencia adquirida y 62% combinada. De todos los grupos etarios, el de 25-36    a&#241;os (promedio de edad 38,7 &plusmn; 15) present&#243; la mayor proporci&#243;n    de casos resistentes (26%). Siete ciudades del Estado concentraron el 59,6%    del total de casos documentados en el estudio. Estos resultados reflejan la    baja calidad de cuidados en salud con los enfermos en estas ciudades. Tambi&#233;n    observamos, la necesidad de mayores cuidados por parte de los m&#233;dicos durante    el tratamiento realizado, con mayor frecuencia, de ex&#225;menes de sensibilidad    a medicamentos anti-TB. El n&#250;mero de casos de TB en Par&#225; no vari&#243;    significativamente durante el periodo estudiado, sin embargo, los investigadores    notaron un ligero aumento en la proporci&#243;n de casos resistentes a medicamentos    relacionados al n&#250;mero total de casos notificados en el Estado. Este cambio    en las tasas de resistencia refleja la necesidad de mejorar la calidad de los    servicios de salud para la atenci&#243;n de TB. La concentraci&#243;n de casos    de tuberculosis se observ&#243; en algunos municipios y barrios de la Ciudad    de Bel&#233;m.</font></p>     <p><font face="Verdana" size="2"><b>Palabras clave: </b><i>Mycobacterium tuberculosis;    </i>Tuberculosis; Resistencia a M&#250;ltiples Medicamentos; Rifampicina; Isoniazida.</font></p> <hr size="1">     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>INTRODUCTION</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">One of the biggest problems to tuberculosis (TB)    control is multidrug-resistant tuberculosis (MDR-TB). While drug-susceptible    TB is effectively treated in most patients, MDR-TB treatment has a success rate    of less than 50%, with high mortality and costs<sup>1,2</sup>. Globally, in    the period from 1994 to 2010, MDR-TB was observed in 3.4% of all new TB cases    and 19.8% of previously treated cases.    The highest global rates of MDR-TB ever reported were documented in 2009 and    2010, justifying continued surveillance of tubercular patients in different    countries<sup>3</sup>. The data about MDR-TB in previously treated individuals    (acquired MDR-TB) reflect poor adherence to therapy, whereas primary cases of    MDR-TB reflect infection transmission in the community.</font></p>     <p><font face="Verdana" size="2">In another report, published in 2000 by the World    Health Organization (WHO), the worldwide prevalence of MDR-TB was given as 7.6%,    with an acquired resistance rate of 0.06%. In 2010, the worldwide prevalence    had fallen to 5.4%, but acquired resistance had risen to 0.36%. The global rates    of acquired resistance in 2000 and 2010 were both lower than the rates obtained    in two earlier investigations conducted in Brazil<sup>4,5</sup>. The first of    these Brazilian studies, which was conducted in 1996-1997, found that 8.5% of    new TB cases were resistant to any drug,    and that 21%of previously treated patients were also resistant. The rates of    primary and acquired MDR-TB were 1.1% and 7.9%, respectively, among patients    who received pre-treatment<sup>6</sup>. Data obtained in the Second National    Inquiry on Resistance to Anti-TB Drugs, performed on 4,421 patients from seven    states, put rates of primary resistance and acquired multidrug resistance at    1.4% and 7.5% respectively. In this more recent study, rates of primary and    acquired MDR-TB remained at levels similar to those of the 1996-1997 study.    Results of studies developed in some individual Brazilian states, however, have    varied considerably. The rates of primary and acquired MDR-TB in the City of    Porto Alegre, Rio Grande do Sul State, were 2.2% and 12.0% respectively<sup>5</sup>.    Researching data collected from 2000 to 2006 in Mato Grosso State by Marques    et al<sup>7</sup> reported primary and acquired rates of MDR-TB of 1.6% and    20.3% respectively. Previous studies performed by the Instituto Evandro Chagas    (IEC) from July 2002 to June 2003 in the School Health Centre of Marco (a type    2 Reference Unit for the treatment of TB located in Bel&#233;m) detected resistance    to any drug in 16% of evaluated cases and primary resistance in 14% of evaluated    cases (own unpublished data). Located in the Brazilian Amazon Region, Par&#225;    State ranks in third position among all Brazilian states in the number of TB    cases and fourth in the number of MDR-TB cases. However, epidemiological information    at the local level remains poor. The purpose of this study was to provide a    fuller epidemiological profile regarding TB resistance of the State. In pursuit    of that goal, this study used routine laboratory results from the IEC and the    Central Laboratory of the State of Par&#225; (LACEN/PA), in order to determine    the frequency of antimicrobial resistance, its epidemiological traits and spatial    distribution.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>MATERIALS AND METHODS</b></font></p>     <p><font face="Verdana" size="2">This study was conducted in Par&#225; State,    Brazil, which has a population of 7,443,904 million individuals and presented    a TB case rate of 47.5 per 100,000 individuals in 2010<sup>8</sup>. An ecological    study was conducted using data from 848 susceptibility tests, which were performed    on 848 tuberculosis patients who met the indicated criteria for such tests:    i) receiving retreatment after failure of the bacteriological standard treatment;    ii) experiencing recidivism of the disease; iii) beginning treatment after abandoning    it; iv) being suspected of primary resistance; v) having contact with a resistant    TB case; vi) being a health professional exposed to TB; vii) being HIV positive;    viii) living on the street; ix) being medically confined; x) being in long-term    care facilities; xi) being a member of indigenous population; and xii) being    attended in hospitals where do not adopt biosecurity measures<sup>9</sup>. Cases    treated between 2005 and 2010 were included in this study. All of susceptibility    tests for <i>Mycobacterium tuberculosis </i>in Par&#225; were performed by the    Public Health Laboratory Network of Par&#225; (constituted by IEC and LACEN/PA)    and included tests for resistance to rifampicin    (R), isoniazid (H), streptomycin (S), pyrazinamide (Z), ethambutol (E) and ethionamide    (Et).</font></p>     <p><font face="Verdana" size="2">A TB case was defined as one for <i>M. tuberculosis    </i>complex culture-confirmed. A case of tuberculosis was defined as drug resistant    (DR-TB) for any type of resistance detected. MDR-TB was defined as resistant    to at least H and R. Poly-resistance was defined as resistant for two or more    drugs in addition to H and R. Primary DR-TB was defined as the presence of resistant    strains of <i>M. tuberculosis </i>in a newly diagnosed patient who had either    never received TB drugs or had received them for less than one month. Acquired    DR-TB was defined as the presence of strains in patients who had previously    received at least one month of TB therapy. Combined resistance was used to refer    to all cases in which resistance was found, no matter the treatment history    of the disease. Prevalence was calculated by dividing the number of positive    cases with the total number of cases tested<sup>10</sup>.</font></p>     <p><font face="Verdana" size="2">Data regarding each individual's sex, age, district,    and status before getting into the program (new case, relapse, failure or abandonment)    and were collected by searching patient files from three sources: the Bacteriology    and Mycology Section/IEC of the Hospital Universit&#225;rio Jo&#227;o de Barros    Barreto, the School Health Centre of Marco    and LACEN/PA.</font></p>     <p><font face="Verdana" size="2">The proportion method recommended by the Brazilian    Ministry of Health was used to evaluate data<sup>9</sup>. Susceptibility tests    were conducted on Lowenstein-Jensen medium. Antibiotics were applied in the    recommended critical concentrations of 0.2 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for H, 40.0 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for R, 2.0 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for E, 25.0 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for Z, 4.0 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for S and 20.0 </font><font size="2">&micro;</font><font face="Verdana" size="2">g/mL    for Et.</font></p>     <p><font face="Verdana" size="2">The spatial distribution of patients in the study    was analysed using the Kernel smoothing technique, a nonparametric method used    to estimate the number of events per unit area in each cell of a regular grid    covering the overall area. The clusters were defined as a geographically bound,    non-random group<sup>11,12</sup>. A bandwidth of 1 km was used for estimating    the Kernel density of MDR-TB patients. The results were depicted graphically    using thematic maps.</font></p>     <p><font face="Verdana" size="2">The ethical clearance for this study was granted    by the IEC (CAAE: 0002.0.072.000-11) on May 25, 2011.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>RESULTS</b></font></p>     <p><font face="Verdana" size="2">Samples taken from 848 tubercular patients were    tested for drug susceptibility, 358 (42.2%) showed some form of resistance.    The annual number of cases for different types of DR-TB is shown in <a href="#t1">table    1</a>. The number of TB cases received to AST and the resistance type (<a href="#t2">Table    2</a>). In some cases, with the isolation of <i>M. tuberculosis </i>resistant    to drugs, there was no information about any kind of previous treatment for    TB (unknown resistance or unknown MDR). The frequency for primary, acquired    and combined DR-TB were 30.4%, 69.3% and 42.2% respectively. MDR-TB was observed    in 223 (26.3%) patients. During the study period, there were 17,983 officially    reported TB cases in Par&#225; State. In this context, the MDR-TB prevalence    was 1.2%. The rates for primary, acquired and combined MDR-TB were 13.7%, 47.7%    and 62.3% respectively.</font></p>     <p><font size="2" face="Verdana"><a name="t1"></a></font></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v3n4/4i03t1.gif" border="0"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><a name="t2"></a></font></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v3n4/4i03t2.gif" border="0"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font face="Verdana" size="2">Of the patients studied, 62.5% were men, and    the average age of the population was 38.7 &plusmn; 15 years old. The age group    most frequently found in the study was from 25 to 34 years old, which together    represented 224 (26%) of all cases in the study. Overall, 79% of patients with    TB and 80% of patients with MDR-TB were between the ages of 15 and 54 years    old.</font></p>     <p><font face="Verdana" size="2">Seven cities (Abaetetuba, Ananindeua, Bel&#233;m,    Bragan&#231;a, Castanhal, Marituba and Santar&#233;m) were responsible for 59.6%    (133/223) of all MDR-TB cases. Of these cases, 43.0% occurred in Bel&#233;m    (96 MDR-TB cases/438 TB cases), followed by 8.1% in Ananindeua (18/70), 2.7%    in Marituba (6/18), 3.1% in Castanhal (7/14), 2.2% in Barcarena (5/11), 2.2%    in Santar&#233;m (5/11), 2.7% in Camet&#225; (6/10) and 0.5% in Abaetetuba (1/8).    The districts in Bel&#233;m with the highest numbers of cases were Guam&#225;    (14 MDR-TB cases/45 TB cases), Jurunas (9/41), Sacramenta (10/33), Marco (5/32),    Pedreira (3/27), Icoaraci (3/26), Terra Firme (6/24) and Marambaia    (4/22).</font></p>     <p><font face="Verdana" size="2">Spacialization was performed on 483 georeferenced    cases of TB. Out of these cases, 59.6% were found to be drug-susceptible, 25.1%    were found to be MDR-TB and 15.3% were found to be resistant TB without also    being MDR-TB<sup>3</sup>. All other cases lacked either the geographical coordinates    or the complete addresses needed for accurate georeferencing. <a href="#f1">Figure    1A</a> evidences the spatial distribution of tuberculosis cases in Par&#225;    State and in <a href="#f1">figure 1B</a>, Bel&#233;m stands out as the Municipality    where the largest number of cases occurred.</font></p>     <p><font size="2" face="Verdana"><a name="f1"></a></font></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v3n4/4i03f1.gif" border="0"></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">The result of applying Kernel smoothing technique    to the points where type 2 TB (MDR) was found can be seen in <a href="#f1">figure    1B</a>. Among many results observed in this figure, what stands out with the    greatest intensity is a hotspot situated in the neighborhood of Guam&#225; (<a href="#f1">Figure    1C</a>). <a href="#f1">Figure 1D</a> shows the SPOT satellite image of Guam&#225;,    where an inordinate distribution of cases can be noticed.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="3"><b>DISCUSSION</b></font></p>     <p><font face="Verdana" size="2">Over the past decade, Brazil has experienced    between 70,000 to 80,000 new TB cases a year. However, data from the Ministry    of Health show that for the first time, the number of new TB cases fell below    70,000. And in 2011, there were only 36 cases of the disease for every 100,000    inhabitants, as opposed to the 42.8 cases recorded for every 100,000 inhabitants    in 2001<sup>13</sup>.</font></p>     <p><font face="Verdana" size="2">By 2010, there were 607 diagnosed cases of MDR-TB    reported in Brazil, as opposed to 334 cases in 2001. It represents an increase    of 82% during the years analyzed. From 2009 to 2010, the growth was very significant,    as 47% more cases were diagnosed<sup>14</sup>.</font></p>     <p><font face="Verdana" size="2">Problems arise when patients are improperly treated    or fail to take their prescribed medications appropriately. Cases in which patients    are retreated (following relapse or readmission after abandonment) are the ones    most likely to lead to an unfavorable outcome, especially among individuals    who have already received more than 30 days of treatment.</font></p>     <p><font face="Verdana" size="2">In Cear&#225; State, the combined MDR-TB rate    for the population studied was 17.7% (266/1500)<sup>15</sup>. The prevalence    rates of primary and acquired resistance in the Federal District of Bras&#237;lia    were 9.2% and 15.8% respectively. For MDR-TB, they were 1.0% and 0%, respectively,    during the period from 1995 to 1997<sup>16</sup>.</font></p>     <p><font face="Verdana" size="2">To ensure that resistance is diagnosed as early    as possible, the WHO and the Brazilian Ministry of Health recommend that healthcare    providers conduct culture and sensitivity testing on all patients who undergo    retreatment. In keeping with this recommendation, completion of culture examinations    grew 156% in retreatment cases from 2001 to 2010, and was 24% higher than it    had been in the last recorded year.</font></p>     <p><font face="Verdana" size="2">Data presented in this study were obtained mainly    from cases of recurrence, abandonment and death, and samples were sent for culture    and susceptibility testing to reference laboratories in Par&#225; State (IEC    and LACEN/PA). This may account for the high prevalence of resistant TB in this    population. Previous studies have revealed great variation in the levels of    resistance detected. Such disparities may be product of different study methodologies    used by different laboratories<sup>5,7,15,16,17,18</sup>.</font></p>     <p><font face="Verdana" size="2">The first vigilance inquiry into resistance,    performed by WHO and the International Union Against Tuberculosis and Lung Disease,    found the following distribution of tuberculosis cases: rates of primary, acquired    and combined MDR-TB were 4.6%, 22.2% and    8.0%, respectively, in Argentina; in Peru, they were 2.5%, 15.7% and 4.5% respectively.    The second inquiry found that rates of primary, acquired and combined MDR-TB remained high, with respective levels    of 3.0%, 12.3% and 4.3% for Peru and 2.5%, 16.7% and 3.5% for Puerto Rico.</font></p>     <p><font face="Verdana" size="2">Knowledge of initial drug resistance is impaired    by the absence of susceptibility testing in diagnosed cases. Failure to perform    or obtain the results of such tests increases the odds of inappropriate treatment,    as well as giving multidrug-resistant bacilli more time to disseminate themselves    in the community<sup>9,19</sup>. The development of MDR-TB worsens disease prognosis    and increases the government's cost of treatment more than 30-fold. This represents    an increase in the average cost of treatment from US$120 (for primary drug-sensitive    TB) to US$3,200 (for MDR-TB). Furthermore, MDR-TB can be transmitted during    the bacillary phase if appropriate therapy is not administered.</font></p>     <p><font face="Verdana" size="2">In our report, the studied population was predominantly    male, as it has been in studies conducted previously by others<sup>7,15,17</sup>.    Regarding the age distribution of cases, 79.4% (673/848) and 80.1% (180/223)    of individuals with TB and MDR-TB, respectively, belonged to the 15 to 54 year    old age group, which is considered an economically active group. Although TB    infection rates remain high among the elderly, the current study observed that    the number of cases in individuals as old as 24 years overlapped with the number    of cases among elderly individuals.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">The capital of the State and the Municipalities    of Abaetetuba, Ananindeua, Castanhal and Marituba had been previously reported    by the high prevalence of TB from 2006 to 2008<sup>20</sup>.</font></p>     <p><font face="Verdana" size="2">The thematic map produced with TB and MDR-TB    data showed the distribution of cases, according to an endemic area. Many MDR-TB    cases are associated with poverty areas with high population density and poor    sanitation. In 1996, the situation of the high number of TB cases in the district    of Guam&#225; was known by the managers of TB control programs in Bel&#233;m,    because Guam&#225; was one of the neighborhoods chosen for collection of material    for the First National Survey of Resistance. The diagnosis and treatment of    new TB cases without intervention habits, and misery situation, seem to have    little impact on reducing the number of new cases. Costa Neto<sup>21</sup> reported    that any intervention for TB control conducted in Vila do Ros&#225;rio, Duque    de Caxias, Rio de Janeiro State, for many years, had little effect on the frequency    of cases, as if an external reservoir to the region was responsible by the ongoing    contamination of people. With poor nutrition and deficient immune system, the    presence of the agent is inevitable.</font></p>     <p><font face="Verdana" size="2">Regarding the cases of MDR-TB observed in the    age group with the highest incidence (25-34 years old), it was observed that    there was a slight increase in the number of cases for 2007. The subsequent    decrease in the number documented of MDR-TB cases may be related to a three-month    interruption of sensitivity testing at the IEC and the replacement of medical    staff at the State Health Reference Unit.</font></p>     <p><font face="Verdana" size="2">The control of MDR-TB depends on, among other    factors, the early diagnosis of resistance, appropriate therapy, improving the    patient's awareness of treatment, and interrupting transmission. The knowledge    of the local epidemiological situation is the first step in raising awareness    in areas with the largest agglomeration of cases.</font></p>     <p><font face="Verdana" size="2">Studies conducted in other countries have demonstrated    that, with the help of educational interventions, patients have come to better    understand information about TB, as well as showing notable improvement with    respect to treatment adherence. Dick and Lombard<sup>22</sup> evaluated the    relationship between health-education approaches and adherence to TB treatment    in two health clinics, with one receiving the intervention and one serving as    a control. In the clinic that received the intervention (which took the form    of an educational pamphlet), researchers found fewer indicators that treatment    had been abandoned than were found in the control group.</font></p>     <p><font face="Verdana" size="2">Improving health literacy is an ongoing project.    The more this process is strengthened, the better patients' health reflexes    will be. An informative booklet about the conduct of patients and contact people    was developed and evaluated by the authors<sup>23</sup>. The booklet provides    information on TB and its prevention, concept, main symptoms, recommendations    for the most effective use of medicines and suggestions of habits that can speed    up the treatment and prevent transmission. The distribution of booklets will    have the partnership of the Secretariat of Health Par&#225; State (SESPA) and    its impact on treatment and outcome of cases, as well as searching the Health    Unit by contact people will be evaluated.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>CONCLUSION</b></font></p>     <p><font face="Verdana" size="2">According to previous studies, the total number    of TB cases in Par&#225; State did not vary significantly during the study period.    There was, however, a slight increase in the number of drug-resistant cases    in proportion to the total number of cases reported to the State. The rates    for primary, acquired and combined MDR-TB in this study were high when compared    to the rates documented in previous inquiries. These resistance rates reflect    the need to improve the quality of health services for patients with tuberculosis.    Seven Municipalities accounted for 59.6% of the total cases in the present study.    A concentration of cases in neighborhoods in the City of Bel&#233;m was also    observed.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="3"><b>ACKNOWLEDGMENTS</b></font></p>     <p><font face="Verdana" size="2">The authors thank to the Director of LACEN/PA,    Drs. Sebasti&#227;o Lic&#237;nio Lira dos Santos and Zelinda Habbid, for giving    data related to the sensitivity test conducted at LACEN from 2008 to 2010 and    Andr&#233;a Pantoja Melo for technical assistance.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>FINANCIAL SUPPORT</b></font></p>     <p><font face="Verdana" size="2">This study was supported by the Instituto Evandro    Chagas, Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel    Superior (CAPES) and the Programa de P&#243;s-gradua&#231;&#227;o em Biologia    Parasit&#225;ria/Universidade Estadual do Par&#225;.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>REFERENCES</b></font></p>     <p><font face="Verdana" size="2">1 World Health Organization. Multidrug and extensively    drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response.    Geneva: WHO; 2010. &#91;<a href="http://www.who.int/tb/features_archive/m_xdrtb_facts/en/" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">2 Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender    T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death    in patients co-infected with tuberculosis and HIV in a rural area of South Africa.    Lancet. 2006 Nov;368(9547):1575-80. Doi: 10.1016/S0140-6736(06)69573-1 &#91;<a href="http://dx.doi.org/10.1016/S0140-6736(06)69573-1" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">3 Zignol M, van Gemert W, Falzon D, Sismanidis    C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance    in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012    Feb;90(2):111-9. Doi: 10.2471/BLT.11.092585 &#91;<a href="http://dx.doi.org/10.2471/BLT.11.092585" target="_blank">Link</a>&#93;</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">4 World Health Organization. Global tuberculosis    report 2012 &#91;Internet&#93;. Geneva: WHO; 2012 &#91;cited 2012 Jul 27&#93;. Available from:    <a href="http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf" target="_blank">http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf</a>.</font></p>     <p><font face="Verdana" size="2">5 Kritski AL. Multidrug-resistant tuberculosis    emergence: a renewed challenge. J Bras Pneumol. 2010 Mar-Apr;36(2):157-8. Doi:    10.1590/ S1806-37132010000200001 &#91;<a href="http://dx.doi.org/10.1590/S1806-37132010000200001" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">6 Braga JU, Barreto AMW, Hijjar MA. Inqu&#233;rito    epidemiol&#243;gico da resist&#234;ncia &#224;s drogas usadas no tratamento    da tuberculose no Brasil 1995-97. Parte III: principais resultados. Bol Pneumol    Sanit. 2003 jan-jun;11(1):76-81. </font></p>     <p><font face="Verdana" size="2">7 Marques M, Cunha EAT, Ruffino-Neto A, Andrade    SMO. Perfil de resist&#234;ncia de <i>Mycobacterium tuberculosis </i>no estado    de Mato Grosso do Sul, 2000-2006. J Bras Pneumol. 2010 mar-abr;36(2):224-31.    Doi: 10.1590/S1806-37132010000200011 &#91;<a href="http://www.scielo.br/scielo.php?pid=S1806-37132010000200011&script=sci_arttext" target="_blank">Link</a>&#93;    </font></p>     <p><font face="Verdana" size="2">8 Minist&#233;rio da Sa&#250;de (BR). Secretaria    de Vigil&#226;ncia em Sa&#250;de. S&#233;rie hist&#243;rica de incid&#234;ncia    de tuberculose no Brasil 2012. Bras&#237;lia: Minist&#233;rio da Sa&#250;de;    2012. </font></p>     <p><font face="Verdana" size="2">9 Minist&#233;rio da Sa&#250;de (BR). Secretaria    de Vigil&#226;ncia em Sa&#250;de. Departamento de Vigil&#226;ncia Epidemiol&#243;gica.    Manual nacional de vigil&#226;ncia laboratorial da tuberculose e outras micobact&#233;rias.    Bras&#237;lia: Minist&#233;rio da Sa&#250;de; 2008. 436 p. &#91;<a href="http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_laboratorial_tuberculose.pdf" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">10 Pablos-M&#233;ndez A, Raviglione MC, Laszlo    A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug    resistance, 1994-1997. N Engl J Med. 1998 Jun;338(23):1641-9. &#91;<a href="http://www.nejm.org/doi/full/10.1056/NEJM199806043382301" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">11 Bailey TC, Gtroll AC. Interactive spatial    data analysis. Harlow: Longman; 1995. 413 p. </font></p>     <p><font face="Verdana" size="2">12 Esri. Essays on geography and GIS. Vol. 5.    Redlands: Esri Press; 2012. 82 p. &#91;<a href="http://www.esri.com/library/bestpractices/essays-on-geography-gis-vol5.pdf" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">13 Minist&#233;rio da Sa&#250;de (BR). Secretaria    de Vigil&#226;ncia em Sa&#250;de. Sistema de Informa&#231;&#227;o de Agravos    de Notifica&#231;&#227;o. S&#233;rie hist&#243;rica da taxa de incid&#234;ncia    da tuberculose. Brasil, Regi&#245;es e Unidades Federadas de resid&#234;ncia    por ano de diagn&#243;stico (1990 a 2011). Bras&#237;lia: Minist&#233;rio da    Sa&#250;de; 2012. </font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">14 Minist&#233;rio da Sa&#250;de (BR). Secretaria    de Vigil&#226;ncia em Sa&#250;de. Departamento de Vigil&#226;ncia Epidemiol&#243;gica.    Programa nacional de controle da tuberculose &#91;Internet&#93;. Bras&#237;lia: Minist&#233;rio    da Sa&#250;de; 2012 &#91;citado 2012 jul 27&#93;. Dispon&#237;vel em: <a href="http://bvsms.saude.gov.br/bvs/publicacoes/ProgramaTB.pdf" target="_blank">http://bvsms.saude.gov.br/bvs/publicacoes/ProgramaTB.pdf</a>.</font></p>     <p><font face="Verdana" size="2">15 Barroso EC, Rodrigues JLN, Pinheiro VGF, Campelo    CL. Preval&#234;ncia da tuberculose multirresistente no Estado do Cear&#225;,    1990-1999. J Pneumol. 2001 nov-dez;27(6):310-4. Doi: 10.1590/S0102-35862001000600004    &#91;<a href="http://dx.doi.org/10.1590/S0102-35862001000600004" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">16 Alvarez TA, Rodrigues MP, Viegas C. Prevalence    of drug-resistant <i>Mycobacterium tubeculosis </i>in patients under intermittent    or daily treatment. J Bras Pneumol. 2009 Jun;35(6):555-60. Doi: 10.1590/S1806-37132009000600009    &#91;<a href="http://dx.doi.org/10.1590/S1806-37132009000600009" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">17 Hiiiar MA, Proc&#243;pio MJ, Freitas LMR,    Guedes R, Bethlem EP. Epidemiologia da tuberculose: import&#226;ncia no mundo,    no Brasil e no Rio de Janeiro. Pulm&#227;o RJ. 2005;14(4):310-4. &#91;<a href="http://www.sopterj.com.br/profissionais/_revista/2005/n_04/08.pdf" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">18 Bastos GM, Cezar MC, Mello FCQ, Conde MB.    Preval&#234;ncia de resist&#234;ncia prim&#225;ria em pacientes com tuberculose    pulmonar sem fatores de risco conhecidos para resist&#234;ncia prim&#225;ria.    J Bras Pneumol. 2012 nov-dez;38(6):733-9. Doi: 10.1590/S1806-37132012000600008    &#91;<a href="http://dx.doi.org/10.1590/S1806-37132012000600008" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">19 Minist&#233;rio da Sa&#250;de (BR). Secretaria    de Vigil&#226;ncia em Sa&#250;de. Manual de recomenda&#231;&#245;es para o controle    da tuberculose no Brasil. Bras&#237;lia: Minist&#233;rio da Sa&#250;de; 2011.    (S&#233;rie A. Normas e manuais t&#233;cnicos). &#91;<a href="http://bvsms.saude.gov.br/bvs/publicacoes/manual_recomendacoes_controle_tuberculose_brasil.pdf" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">20 Ribeiro WA. Tuberculose: um perfil epidemiol&#243;gico    dos munic&#237;pios de Bel&#233;m e Ananindeua-PA no per&#237;odo de 2006 a    2008. Rev Para Med. 2011 jan-mar;25(1):1-7. &#91;<a href="http://files.bvs.br/upload/S/0101-5907/2011/v25n1/a2581.pdf" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">21 Costa-Neto C. Vila Ros&#225;rio e a Cadeia    da Mis&#233;ria: a caminho da elimina&#231;&#227;o da tuberculose. Rev Bras    Pneumol Sanit. 2007 dez;15(1):15-28. &#91;<a href="http://scielo.iec.pa.gov.br/scielo.php?script=sci_arttext&pid=S1982-32582007000100004&lng=pt&nrm=iso&tlng=pt" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">22 Dick J, Lombard C. Shared vision: a health    education project designed to enhance dherence to anti-tuberculosis treatment.    Int J Tuberc Lung Dis. 1997 Apr;1(2):181-6. &#91;<a href="http://www.ingentaconnect.com/content/iuatld/ijtld/1997/00000001/00000002/art00015?token=00541cb6062a5542cc88383a4b3b25702e7b75245a38533b4767732a726e2d2954496f642f466f2ba825" target="_blank">Link</a>&#93;</font></p>     <p><font face="Verdana" size="2">23 Apolinario D, Braga RCOP, Magaldi RM, Busse    AL, Campora F, Brucki S, et al. Short assessment of health literacy for portuguese-speaking    adults. Rev Saude Publica. 2012 Jul;46(4):702-11. Doi: 10.1590/S0034-89102012005000047    &#91;<a href="http://dx.doi.org/10.1590/S0034-89102012005000047" target="_blank">Link</a>&#93;</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b><a name="endereco"></a><a href="#topo"><img src="/img/revistas/ess/v20n1/seta.gif" border="0"></a>Correspondence    /Correspond&#234;ncia / Correspondencia:</b></font>    <br>   <font face="Verdana" size="2">Karla Val&#233;ria Batista Lima    <br>   </font><font face="Verdana" size="2">Instituto Evandro Chagas,    <br>   Se&#231;&#227;o de Bacteriologia e Micologia    <br>   Rodovia BR 316, km 7, s/n.     <br>   Bairro: Levil&#226;ndia CEP: 67030-000    <br>   Ananindeua-Par&#225;-Brasil    <br>   E-mail: <a href="mailto:karlavaleria_2007@hotmail.com">karlavaleria_2007@hotmail.com</a></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Received / Recebido em / Recibido en: 29/4/2012    <br>   Accepted / Aceito em / Aceito en: 6/10/2012</font></p>     <p>&nbsp;</p>    <script type="text/javascript"> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));   </script>   <script type="text/javascript"> try { var pageTracker = _gat._getTracker("UA-7885746-4"); pageTracker._setDomainName("none"); pageTracker._setAllowLinker(true); pageTracker._trackPageview(); } catch(err) {}</script>      ]]></body>
</article>
